Intuitive Surgical — Business Overview

What does Intuitive Surgical do?

Intuitive Surgical makes robotic-assisted surgery systems and sells the instruments, accessories, and services that keep those systems running. Founded in 1995 and headquartered in Sunnyvale, California, the company builds technology that allows surgeons to perform minimally invasive procedures — operations that involve smaller incisions, less pain, and faster recovery than traditional open surgery. The surgeon sits at a console and controls robotic arms that hold tiny instruments inside the patient, guided by a high-definition 3D camera.

The company's two main platforms serve surgery and diagnostics. The da Vinci surgical system is the flagship product, covering procedures across general surgery, urology, gynecology, cardiothoracic surgery, and head and neck surgery — over 70 recognized clinical uses in total. The newer Ion endoluminal system, cleared by the FDA in 2019, is a flexible, catheter-based robot designed for minimally invasive lung biopsies, extending Intuitive's reach beyond the operating room into diagnostics.

The business operates as a single reporting segment, so there is no formal breakdown of revenue and margin by product line in the filing. However, the company's revenue comes from three broad streams: system sales (capital equipment), instruments and accessories (consumables), and services — with consumables and services forming the recurring, high-frequency portion of revenue.

How does Intuitive Surgical make money?

Intuitive uses a classic "razor and blade" model. Hospitals make a large upfront capital purchase to acquire a da Vinci or Ion system — a lengthy sales cycle often shaped by hospital budget cycles and capital spending priorities. Once a system is installed, the hospital must continually buy instruments and accessories (most are designed for a limited number of uses before replacement) and pay for service contracts. This means every new system placed is a long-term revenue stream, not a one-time sale.

The consumables business is inherently tied to procedure volume. Instruments wear out and are replaced on a per-procedure basis. As the installed base of systems grows and surgeons perform more procedures, instrument and accessory revenue compounds. This makes procedure volume — how many surgeries are performed with da Vinci or Ion systems globally — a key driver of the business. The company also earns service revenue through maintenance contracts, 24/7 technical support, software upgrades, and a growing suite of digital tools including analytics dashboards and virtual reality simulation training.

What market does Intuitive Surgical operate in?

Intuitive competes within the broader surgical robotics and minimally invasive surgery market, which sits inside the much larger global medical device industry. The company's products address surgical specialties that, combined, represent tens of millions of procedures performed annually worldwide. The filing does not cite a specific total addressable market figure, but it notes more than 70 clinical applications for da Vinci alone.

The secular trend strongly favors minimally invasive care. There is a documented global shift away from open surgery toward approaches that result in shorter hospital stays, fewer complications, and faster patient recovery. Intuitive frames itself as a direct beneficiary of this trend, positioning its platforms as the preferred vehicle for delivering minimally invasive care at scale. At the same time, healthcare systems worldwide are under cost pressure, which creates both an opportunity (robotic surgery can reduce total cost per episode) and a risk (hospitals scrutinize capital spending carefully, and payors generally do not reimburse more for robotic procedures than for conventional ones).

Who are Intuitive Surgical's main competitors?

Intuitive's primary competition is not just other robots — it is every alternative way to perform or avoid a procedure. The filing explicitly lists open surgery, conventional laparoscopic surgery, drug therapies, and radiation as competitive alternatives. Because many of these approaches are deeply entrenched and widely reimbursed, gaining and holding procedure share requires continuous clinical evidence and surgeon education.

In the robotic space specifically, competition is growing. The filing names a long list of companies that have introduced or are developing robotic-assisted surgical products, including:

• Johnson & Johnson (Ottava system in development)
• Medtronic plc (Hugo robotic-assisted surgery system)
• CMR Surgical Ltd.
• Distalmotion SA
• Multiple Chinese entrants, including Shanghai Microport Medbot, Shenzhen Edge Medical, Harbin Sizhe Rui, and others — with the filing specifically flagging increasing competition within China
• Noah Medical Corporation (lung biopsy, competing with Ion)

Intuitive's claimed competitive advantages are substantial but not impenetrable. The company holds more than 5,600 active patents and more than 2,500 pending worldwide, has over 25 years of installed base and clinical data, and benefits from deep surgeon training and loyalty. Its ecosystem — linking systems, instruments, data analytics, training, and support — creates meaningful switching costs. However, the filing acknowledges that newer entrants could reduce pricing power, and that anticipation of competing products can itself dampen customer purchasing.

Where does Intuitive Surgical operate?

The United States is Intuitive's largest market by far, and its share is growing. Domestic revenue represented 68% of total revenue in 2025, up from 66% in 2023. The company sells directly in the U.S., Europe (most major markets), Japan, South Korea, India, Taiwan, and Canada.

Outside the U.S., Europe and Asia are the key regions. In markets such as Italy, Spain, Portugal, Greece, Eastern Europe, and most of the rest of the world, Intuitive sells through distributors. In China, the company operates through a majority-owned joint venture with Fosun Pharma, called Intuitive Surgical-Fosun, which handles both sales and manufacturing in Shanghai. China is a strategically important but uncertain market — the Chinese government has implemented a quota system allowing only 559 new surgical robots to be sold under its current five-year plan, and sales depend on hospitals completing a formal tender and approval process.

Manufacturing is spread across several countries. Robotic systems are built in Sunnyvale, California; Peachtree Corners, Georgia; and Shanghai, China. Instruments and accessories are produced in Sunnyvale and Mexicali, Mexico. Ion-related components are made in Blacksburg, Virginia, and endoscope components come from Parvomay, Bulgaria and multiple sites in Germany. The company employs approximately 17,021 full-time employees across 29 countries.